Skip to main content

Advertisement

Log in

Fabry Disease Practice Guidelines: Recommendations of the National Society of Genetic Counselors

  • PROFESSIONAL ISSUES
  • Published:
Journal of Genetic Counseling

Abstract

Identification and comprehensive care of individuals who have Fabry disease (FD) requires a multidisciplinary approach inclusive of genetic testing, test interpretation, genetic counseling, long term disease symptom monitoring, treatment recommendations, and coordination of therapy. The purpose of this document is to provide health care professionals with guidelines for testing, care coordination, identification of psychosocial issues, and to facilitate a better understanding of disease treatment expert recommendations for patients with Fabry disease. These recommendations are the opinions of a multicenter working group of genetic counselors, medical geneticists, and other health professionals with expertise in Fabry disease counseling, as well as representatives/founders of the two United States based Fabry disease patient advocacy groups who are themselves affected by Fabry disease. The recommendations are U.S. Preventive Task Force Class III, and they are based on clinical experience, a review of pertinent English-language articles, and reports of expert committees. This document reviews the genetics of Fabry disease, the indications for genetic testing, interpretation of results, psychosocial considerations, and references to professional and patient resources.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1

Similar content being viewed by others

References

  • Abe, A., Gregory, S., Lee, L., Killen, P. D., Brady, R. O., Kulkarni, A., et al. (2000). Reduction of globotriaosylceramide in Fabry disease mice by substrate deprivation. The Journal of Clinical Investigation, 105, 1563–1571.

    Article  PubMed  CAS  Google Scholar 

  • Albano, L. M., Rivitti, C., Bertola, D. R., Honjo, R. S., Kelmann, S. V., Giugliana, R., et al. (2010). Angiokeratoma: a cutaneous marker of Fabry’s disease. Clinical and Experimental Dermatology, 35(5), 505–508.

    Article  PubMed  CAS  Google Scholar 

  • Ashton-Prolla, P., Tong, B., Shabeer, J., Eng, C. M., & Desnick, R. J. (2000). 22 novel mutations in the alpha-galactosidase A gene and genotype/phenotype correlations including mild hemizygotes and severely affected heterozygotes. Journal of Investigative Medicine, 48, 227.

    PubMed  CAS  Google Scholar 

  • Banikazemi, M., Bultas, J., Waldek, S., Wilcox, W. R., Whitley, C. B., McDonald, M., et al. (2007). Agalsidase-beta therapy for advanced Fabry disease: a randomized trial. Annals of Internal Medicine, 146(2), 77–86.

    Article  PubMed  Google Scholar 

  • Bennett, R. L. (2010a). The practical guide to the genetic family history (2nd ed.). Hoboken: Blackwell.

    Book  Google Scholar 

  • Bennett, R. L. (2010b). Genetic counseling and psychosocial issues for individuals and their families with Fabry disease. In Elstein D, Altarescu G, Beck M (Eds.), Fabry disease. New York: Springer.

  • Bennett, R. L., Steinhaus, K. A., Uhrich, S. B., O’Sullivan, C. K., Resta, R. G., Lochner-Doyle, D., et al. (1995). Recommendations for standardized pedigree nomenclature. American Journal of Human Genetics, 56, 745–752.

    PubMed  CAS  Google Scholar 

  • Bennett, R. L., Hart, K. A., O’Rourke, E. O., et al. (2002). Fabry disease in genetic counseling practice: recommendations of the National Society of Genetic Counselors. Journal of Genetic Counseling, 11(2), 121–146.

    Article  PubMed  Google Scholar 

  • Bennett, R. L., Steinhaus, K. A., Resta, R. G., & Doyle, D. L. (2008). Standardized human pedigree nomenclature: update and assessment of the recommendations of the National Society of Genetic Counselors. Journal of Genetic Counseling, 7(5), 424–433.

    Article  Google Scholar 

  • Brady, R. O., & Schiffmann, R. (2000). Clinical features of and recent advances in therapy for Fabry disease. Journal of the American Medical Association, 284, 2771–2775.

    Article  PubMed  CAS  Google Scholar 

  • Brower, A., Hoffman, A. J., Thompson, B. H, & Watson, M. S. (2011). Utilization of the newborn screening translational research network to advance research and clinical applications in lysosomal storage disorders. 7th WORLD symposium 2011.

  • Chimenti, C., Pieroni, M., Morgante, E., et al. (2004). Prevalaence of Fabry disease in female patients with late-onset hypertrophic cardiomyopathy. Circulation, 110(9), 1047–1053. Epub 2004 Aug 16.

    Article  PubMed  CAS  Google Scholar 

  • Clarke, A. (Ed.). (1998). The genetic testing of children. Oxford: BIOS Scientific.

    Google Scholar 

  • Clarke, A., & Flinter, F. (1996). The genetic testing of children: A clinical perspective. In T. Marteau & M. Richards (Eds.), The troubled helix: Social and psychological implications of the new human genetics (pp. 164–176). New York: Cambridge University Press.

    Chapter  Google Scholar 

  • Colombi, A., Kostyal, A., Bracher, R., Gloor, F., Mazzi, R., & Tholen, H. (1967). Angiokeratoma corporis diffusum: Fabry’s disease. Helvetica Medica Acta, 34, 67–83.

    PubMed  CAS  Google Scholar 

  • Davis, D. S. (1997). Genetic dilemmas and the child’s right to an open future. The Hastings Center Report, 27, 7–15.

    Article  PubMed  CAS  Google Scholar 

  • Desnick, R. J. (2004). Enzyme replacement therapy for Fabry disease: lessons from two alpha-galactosidase A orphan products and one FDA approval. Expert Opinion on Biological Therapy, 4, 1167–1176.

    Article  PubMed  CAS  Google Scholar 

  • Desnick, R., & Ioannou, Y., (2006). Eng C. α-Galactosidase A deficiency: Fabry disease. In: Valle D, Baudette A, Vogelstein KC, (Eds.), The online metabolic & molecular bases of inherited disease. McGraw-Hill Companies Inc. www.ommbid.com, accessed Mar 2011.

  • Desnick, R. J., Brady, R., Barranger, J., et al. (2003). Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy. Annals of Internal Medicine, 138, 338–346.

    Article  PubMed  Google Scholar 

  • Dink, A., Sims, I., Pay, S., Calgary, K., & Can, C. (2000). Fabry’s disease mimicking familial Mediterranean fever. Clinical and Experimental Rheumatic, 18, 787–788.

    Google Scholar 

  • Elstein, D., Altars, G., & Beck, M. (ends) (2010). Fabry disease, Springer.

  • Eng, C. M., Banikazemi, M., Gordon, R. E., Goldman, M., Phelps, R., Kim, L., et al. (2001a). A phase 1/2 clinical trial of enzyme replacement in Fabry disease: pharmacokinetic, substrate clearance, and safety studies. American Journal of Human Genetics, 68, 711–722.

    Article  PubMed  CAS  Google Scholar 

  • Eng, C. M., Guffon, N., Wilcox, W. R., Germain, D. P., Lee, P., Waldek, S., et al. (2001b). Safety and efficacy of recombinant human ®-galactosidase A replacement therapy in Fairy’s disease. The New England Journal of Medicine, 345, 9–16.

    Article  CAS  Google Scholar 

  • Eng, C. M., Germain, D. P., Banikazemi, M., Warnock, D. G., Wanner, C., Hopkin, R. J., et al. (2006). Fabry disease: guidelines for the evaluation and management of multi-organ system involvement. Genetics in Medicine, 8(9), 539–548.

    Article  PubMed  Google Scholar 

  • Gahl, W. A. (2001). New therapies for Fabry’s disease. The New England Journal of Medicine, 345, 55–57.

    Article  PubMed  CAS  Google Scholar 

  • Germain, D. P. (2010). Fabry disease. Orphanet Journal of Rare Diseases, 5, 30. Review.

    Article  PubMed  Google Scholar 

  • Gibas, A. L., Klatt, R., Johnson, J., Clarket, J. T. R., & Katz, J. (2008). Disease rarity, carrier status, and genera: a triple disadvantage for women with Fabry disease. Journal of Genetic Counseling, 17, 528–537.

    Article  PubMed  Google Scholar 

  • Grewal, R. P. (1993). Psychiatric disorders in patients with Fabry’s disease. International Journal of Psychiatry in Medicine, 23, 307–312.

    Article  PubMed  CAS  Google Scholar 

  • Hershberger, R. E., Lindenfeld, J., Mestroni, L., Seidman, C. E., Taylor, M. R. G., & Towbin, J. A. (2009). Journal of Cardiac Failure, 15(2), 83–97.

    Article  PubMed  Google Scholar 

  • Holmes, L. B., Harvey, E. A., Coull, B. A., Huntington, K. B., Khoshbin, S., Hayes, A. M., et al. (2001). The teratogenicity of anticonvulsant drugs. The New England Journal of Medicine, 344, 1132–1138.

    Article  PubMed  CAS  Google Scholar 

  • Hopkin, R. J., Bissler, J., Banikazemi, M., Clarke, L., Eng, C. M., Germain, D. P., et al. (2008). Characterization of Fabry disease in 352 pediatric patients in the Fabry Registry. Pediatric Research, 64, 550–555.

    Article  PubMed  Google Scholar 

  • Laney, D. A., & Fernhoff, P. M. (2008). Diagnosis of Fabry disease via analysis of family history. Journal of Genetic Counseling, 17(1), 79–83.

    Article  PubMed  Google Scholar 

  • Laney, D.A., Gruskin, D.J., Fernhoff, P.M., Cubells, J.F., Ousley, O.Y., Hipp, H., et al. (2010). Social-adaptive and psychological functioning of patients affected by fabry disease. Journal of Inherited Metabolic Disease. Online.

  • Lee, K., Jin, X., Zhang, K., Copertino, L., Andrews, L., Baker-Malcolm, J., et al. (2003). A biochemical and pharmacological comparison of enzyme replacement therapies for the glycolipid storage disorder Fabry disease. Glycobiology, 13, 305–313.

    Article  PubMed  Google Scholar 

  • Lidov, O., West, M., Pintos-Morell, G., et al. (2010). Effects of enzyme replacement therapy in Fabry disease—A comprehensive review of the medical literature. Genetics in Medicine, 12(11).

  • Lin, H. Y., Chong, K. W., Hsu, J. H., et al. (2009). High incidence of the cardiac variant of Fabry disease revealed by newborn screening in the Taiwan Chinese population. Circulation. Cardiovascular Genetics, 2, 450–456.

    Article  PubMed  Google Scholar 

  • MacDermot, K. D., Holmes, A., & Miners, A. H. (2001a). Anderson Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males. Journal of Medical Genetics, 38, 750–760.

    Article  PubMed  CAS  Google Scholar 

  • MacDermot, K. D., Holmes, A., & Miners, A. H. (2001b). Anderson Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females. Journal of Medical Genetics, 38, 769–775.

    Article  PubMed  CAS  Google Scholar 

  • McConkie-Rosell, A., & DeVellis, B. M. (2000). Threat to parental role: a possible mechanism of altered self-concept related to carrier knowledge. Journal of Genetic Counseling, 9, 285–302.

    Article  Google Scholar 

  • Mehta, A., Ricci, R., Widmer, U., et al. (2004). Fabry disease defined, baseline clinical manifestations of 366 patients in the Fabry outcome survey. European Journal of Clinical Investigation, 34(3), 235–242.

    Article  Google Scholar 

  • Mehta, A., Beck, M., & Sunder-Plassmann, G. (Eds.). (2006). Fabry disease: Perspectives from 5 years of FOS. Oxford: Oxford PharmaGenesis.

    Google Scholar 

  • Meikle, P. J., Hopwood, J. J., Clague, A. E., & Carey, W. F. (1999). Prevalence of lysosomal storage disorders. Journal of the American Medical Association, 281, 249–254.

    Article  PubMed  CAS  Google Scholar 

  • Michie, S. (1996). Predictive genetic testing in children: Paternalism or empiricisms? In T. Marteau & M. Richards (Eds.), The troubled helix: Social and psychological implications of the new human genetics (pp. 177–183). New York: Cambridge University Press.

    Chapter  Google Scholar 

  • Motabar, O., Sidransky, E., Goldin, E., & Zheng, W. (2010). Fabry disease- current treatment and new drug development. Current Chemical Genomics, 4, 50–56.

    Article  PubMed  CAS  Google Scholar 

  • National Society of Genetic Counselors. (1995). National Society of Genetic Counselors, Position statement on prenatal and childhood testing for adult-onset disorders. Perspectives Genetic Counseling, 17, 5.

    Google Scholar 

  • Ortiz, A., Oliveira, J. P., Waldek, S., Warnock, D. G., Cianciaruso, B., Wanner, C., et al. (2008a). Nephropathy in males and females with Fabry disease: cross-sectional description of patients before treatment with enzyme replacement therapy. Nephrology, Dialysis, Transplantation, 23, 1600–1607.

    Article  PubMed  CAS  Google Scholar 

  • Ortiz, A., Oliveira, J. P., Wanner, C., Brenner, B. M., Waldek, S., & Warnock, D. G. (2008b). Recommendations and guidelines for the diagnosis and treatment of Fabry nephropathy in adults. Nature Clinical Practice Nephrology, 4(6), 327–336.

    Article  PubMed  Google Scholar 

  • Ramaswami, U., Whybra, C., Parini, R., et al. (2006). Clinical manifestations of Fabry disease in children: data from the Fabry Outcome Survey. Acta Paediatrica, 95, 86–92.

    Article  PubMed  Google Scholar 

  • Resta, R. G. (Ed.). (2000). Psyche and helix, Psychological aspects of genetic counseling. Essays by Seymour Kessler, PhD. New York: Wiley-Liss.

    Google Scholar 

  • Ries, M., Gupta, S., Moore, D. F., Sachdev, V., Quirk, J. M., Murray, G. J., et al. (2005). Pediatric Fabry disease. Pediatrics, 115(3), e344–e355. Resta RG (ed) (2000).

    Article  PubMed  Google Scholar 

  • Schiffmann, R., Murray, G. J., Treco, D., Daniel, P., Sellos-Moura, M., Myers, M., et al. (2000). Infusion of α-galactosidase A reduces tissue globotriaosylceramide storage in patients with Fabry disease. PNAS, 97, 365–370.

  • Schiffmann, R., Kopp, J. B., Austin, H. A., Sabnis, S., Moore, D. F., Weibel, T., et al. (2001). Enzyme replacement therapy in Fabry disease. A randomized controlled trial. Journal of the American Medical Association, 285, 2743–2749.

    Article  PubMed  CAS  Google Scholar 

  • Scott, C. R., Elliot, S., Glass, M., Buroker, N., Thomas, L., Keutzer, J., et al. (2011). Gelb MH (2011) Application of a triplex assay by MS/MS for the detection of Fabry, Pompe, and MPS-I within a newborn screening laboratory. 7th WORLD symposium

  • Sims, K., Politei, J., Banikazemi, M., & Lee, P. (2009). Stroke in Fabry disease frequently occurs before diagnosis and in the absence of other clinical events: Natural history data from the Fabry registry. Stroke, 40, 788–794.

    Article  PubMed  Google Scholar 

  • Sørensen, S. A., & Hasholt, L. (1983). Attitudes of persons at risk for Fabry’s disease towards predictive tests and genetic counseling. Journal of Biosocial Science, 15, 89–94.

    Article  PubMed  Google Scholar 

  • Street, N. J., Yi, M. S., Bailey, L. A., & Hopkin, R. J. (2006). Comparison of health-related quality of life between heterozygous women with Fabry disease, a healthy control population, and patients with other chronic disease. Genetics in Medicine, 8(6), 346–353.

    Article  PubMed  Google Scholar 

  • Stryker, V. L., & Kreps, C. (2001). Fabry disease. The American Journal of Nursing, 101, 39–44.

    Article  PubMed  CAS  Google Scholar 

  • Tøndel, C., Bostad, L., Larsen, K., et al. (2013). Agalsidase benefits renal hisotology in young patients with Fabry disease. Journal of the American Society of Nephrology, 24, 137–148.

    Article  PubMed  Google Scholar 

  • Uhlmann, W. R., Schuette, J. L., & Yashar, B. (2009). A guide to genetic counseling (2nd ed.). Hoboken: Wiley Blackwell.

    Google Scholar 

  • Vedder, A. C., Linthorst, G. E., Houge, G., Groener, J. E., Ormel, E. E., Bouma, B. J., et al. (2007). Treatment of Fabry disease: outcome of a comparative trial with agalsidase alfa or beta at a dose of 0.2mg/kg. PLoS One, 2(7), e598.

    Article  PubMed  Google Scholar 

  • Waldek, S., Patel, M. R., Banikazemi, M., Lemay, R., & Lee, P. (2009). Life expectancy and cause of death in males and females with Fabry disease: findings from the Fabry registry. Genetics in Medicine, 11(11), 790–796.

    Article  PubMed  Google Scholar 

  • Wang, R. Y., Lelis, A., Mirocha, J., & Wilcox, W. R. (2007). Heterozygous Fabry women are not just carriers, but have a significant burden of disease and impaired quality of life. Genetics in Medicine, 9(1), 34–45.

    Article  PubMed  CAS  Google Scholar 

  • Wang, R. Y., Bodamer, O. A., Watson, M. S., Wilcox, W. R., & on behalf of the ACMG Work Group on Diagnostic Confirmation of Lysosomal Storage Diseases. (2011). Lysosomal storage diseases: diagnostic confirmation and management of presymptomatic individuals. Genetics in Medicine, 13(5), 457–484.

    Article  PubMed  Google Scholar 

  • Watt, T., Burlina, A. P., Cazzorla, C., Schönfeld, D., Banikazemi, M., Hopkin, R. J., et al. (2010). Agalsidase beta treatment is associated with improved quality of life in patients with Fabry disease: findings from the Fabry Registry. Genetics in Medicine, 12(11), 703–712.

    Article  PubMed  CAS  Google Scholar 

  • Weil, J. (2000). Psychosocial genetic counseling. Oxford: Oxford University Press.

    Google Scholar 

  • Wertz, D., Fanos, J. H., & Reilly, P. R. (1994). Genetic testing for children and adolescents: who decides? Journal of the American Medical Association, 272, 875–881.

    Article  PubMed  CAS  Google Scholar 

  • Wilcox, W. R., Oliveira, J. P., Hopkin, R. J., Ortiz, A., Banikazemi, M., Feldt-Rasmussen, U., et al. (2008). Females with Fabry disease frequently have major organ involvement: lessons from the Fabry registry. Molecular Genetics and Metabolism, 93(2), 112–128.

    Article  PubMed  CAS  Google Scholar 

  • Williams, J. K., Schutte, D. L., Evers, C., & Holkup, P. A. (2000). Redefinition: coping with normal results from predictive gene testing for neurodegenerative disorders. Research in Nursing & Health, 23, 260–269.

    Article  CAS  Google Scholar 

  • Wise, D., Wallace, H. F., & Jellinek, E. H. (1962). Angiokeratoma corporis diffusum. Oxford Journals Medicine New Series, XXXI(122), 177–212.

    Google Scholar 

  • Yasuda, M., Shabbeer, J., Benson, S. D., Maire, I., Burnett, R. M., & Desnick, R. J. (2003). Fabry disease: characterization of alpha-galactosidase A double mutations and the D313Y plasma enzyme pseudodeficiency allele. Human Mutation, 22, 486–492.

    Article  PubMed  CAS  Google Scholar 

  • Zarate, Y. A., & Hopkin, R. J. (2008). Fabry’s disease. Lancet, 372(9647), 1427–1435.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

The authors of the paper would like to thank the Fabry patients and family members who teach us as we work together to learn more about Fabry disease.

Disclaimers

The Fabry Support and Information Group (FSIG) has received donations from Genzyme Corporation (the manufacturer of Fabrazyme®, a drug referenced in these guidelines), Shire Human Genetic Therapies, Inc. (the manufacturer of Replagal®, a drug referenced in these guidelines), and Amicus Therapeutics. The National Fabry Disease Foundation has received donations from Genzyme Corporation, Shire Human Genetic Therapies and Amicus Therapeutics. The authors and reviewers of this paper volunteered their time, and did not receive an honorarium.

The practice guidelines of the National Society of Genetic Counselors (NSGC) are developed by members of the NSGC to assist genetic counselors and other health care providers in making decisions about appropriate management of genetic concerns; including access to and/or delivery of services. Each practice guideline focuses on a clinical or practice-based issue, and is the result of a review and analysis of current professional literature believed to be reliable. As such, information and recommendations within the NSGC practice guidelines reflect the current scientific and clinical knowledge at the time of publication, are only current as of their publication date, and are subject to change without notice as advances emerge.

In addition, variations in practice, which take into account the needs of the individual patient and the resources and limitations unique to the institution or type of practice, may warrant approaches, treatments and/or procedures that differ from the recommendations outlined in this guideline. Therefore, these recommendations should not be construed as dictating an exclusive course of management, nor does the use of such recommendations guarantee a particular outcome. Genetic counseling practice guidelines are never intended to displace a health care provider’s best medical judgment based on the clinical circumstances of a particular patient or patient population. Practice guidelines are published by NSGC for educational and informational purposes only, and NSGC does not “approve” or “endorse” any specific methods, practices, or sources of information.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Dawn A. Laney.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Laney, D.A., Bennett, R.L., Clarke, V. et al. Fabry Disease Practice Guidelines: Recommendations of the National Society of Genetic Counselors. J Genet Counsel 22, 555–564 (2013). https://doi.org/10.1007/s10897-013-9613-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10897-013-9613-3

Keywords

Navigation